We play an active role in breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
Our team produces media releases, reports, policy papers and other informative content to keep you up to date on the most pressing issues facing our industry. Here in our resources section, you’ll find our most recent work.
Many new therapies coming to the market are not well served by the traditional drug reimbursement approaches currently employed by Canada’s public plans. A growing number of European regulatory authorities have been using novel managed entry agreements (MEA) and innovative access agreements (IAA) to accelerate approval times and improve availability to patients.
The innovative pharmaceutical industry has sponsored over two-thirds of clinical trials initiated in Canada in the last 5 years and contributed over $15 billion to the Canadian economy annually.
A growing number of payers in many countries are looking to managed entry agreements (MEAs) and other innovative access arrangements (IAAs) to allow rapid access to medicines that address significant unmet needs.
Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022
Our Code of Ethical Practices guides the activities of all our members’ employees as they interact with stakeholders to commercialize prescription medicines (excluding medical devices and over-the-counter products). Adherence to the Code is a condition of membership.
The process for Canadians to access new medicines is extremely complex and involves several different federal, provincial, and territorial agencies. It takes two years following approval (732 days) for Canadian patients to get access to a drug in the public plan, whereas those in the private plan get access to a drug in less than one year (226 days).
Canadians relying on public insurance plans face significant delays accessing new medicines. This graph breaks down the sequential approval and listing process, and demonstrates how long it takes Canadians to access innovative medicines.
More than 23-million Canadians depend on access to medicines and vaccines through employer-sponsored private plans.
Use this tool to search for brand name drugs to view their current negotiation status.
Learn more about the negotiation process from the pCPA.
One of Innovative Medicines Canada’s guiding principles is to offer solutions to challenges in the Canadian health system. Access to new medicines is one such challenge.
Use this beginner’s guide to understand the basics of how our industry works.
Everything you need to make an informed decision about our industry.
Breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
Informative content to keep you up to date on the most pressing issues facing our industry.
